Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.41 |
| ▸ | JAK3 | P52333 | 7/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ADA | P00813 | 2/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21555751 | 1.00 | JAK2 (0.41) | JAK2JAK3TLR7ADASMPD3 | |
| SCHEMBL21555749 | 0.95 | JAK2 (0.40) | JAK2JAK3TLR7ADASMPD3 | |
| SCHEMBL30393636 | 0.71 | PDE2A (0.39) | JAK2JAK3PIK3CG | |
| SCHEMBL3468681 | 0.70 | HTR6 (0.41) | JAK2JAK3TLR7SMPD3PIK3CG | |
| SCHEMBL21585151 | 0.70 | JAK2 (0.43) | JAK2JAK3SMPD3PIK3CG | |
| SCHEMBL24983902 | 0.69 | APOBEC3A (0.38) | — | |
| SCHEMBL30393510 | 0.69 | PDE2A (0.39) | JAK2JAK3PIK3CG | |
| SCHEMBL30574607 | 0.69 | PIK3CG (0.38) | JAK2JAK3ADAPIK3CG | |
| SCHEMBL21883583 | 0.67 | ADA (0.40) | TLR7ADA | |
| SCHEMBL20621502 | 0.67 | ADA (0.40) | TLR7ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | JAK2 59/4885JAK3 118/4885TLR7 3424/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | JAK2 40/4885JAK3 83/4885TLR7 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.